Advances in the treatment of congestive heart failure

New approaches for an old disease

Maryann Z. Skrabal, Julie A. Stading, Kathryn A. Behmer-Miller, Daniel E. Hilleman

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Heart failure is a symptom complex of varied etiology associated with substantial mortality. Approximately 5 million Americans have the disease, with 400,000 new cases diagnosed each year. DeSpite better understanding of its pathophysiology, therapeutic options remain suboptimal and the syndrome remains associated with high rates of hospitalization and loss of economic productivity. Management traditionally included vasodilators, diuretics, and digoxin, with a focus on controlling symptoms and improving ejection fraction and exercise capacity. Drug therapy now is focused on improving survival, with a reduction in health care costs related to hospitalizations. Drugs with a proven benefit in reducing morbidity and mortality are angiotensin- converting enzyme inhibitors, β-blockers, and the combination of hydralazine plus a nitrate. Diuretics, digoxin, dihydropyridine calcium channel blockers, phosphodiesterase inhibitors, catecholamine infusions, amiodarone, left ventricular assist devices, and transplantation are also options.

Original languageEnglish
Pages (from-to)787-804
Number of pages18
JournalPharmacotherapy
Volume20
Issue number7 I
StatePublished - 2000

Fingerprint

Digoxin
Diuretics
Hospitalization
Heart Failure
Hydralazine
Heart-Assist Devices
Phosphodiesterase Inhibitors
Amiodarone
Mortality
Calcium Channel Blockers
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Health Care Costs
Nitrates
Catecholamines
Transplantation
Economics
Morbidity
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Skrabal, M. Z., Stading, J. A., Behmer-Miller, K. A., & Hilleman, D. E. (2000). Advances in the treatment of congestive heart failure: New approaches for an old disease. Pharmacotherapy, 20(7 I), 787-804.

Advances in the treatment of congestive heart failure : New approaches for an old disease. / Skrabal, Maryann Z.; Stading, Julie A.; Behmer-Miller, Kathryn A.; Hilleman, Daniel E.

In: Pharmacotherapy, Vol. 20, No. 7 I, 2000, p. 787-804.

Research output: Contribution to journalReview article

Skrabal, MZ, Stading, JA, Behmer-Miller, KA & Hilleman, DE 2000, 'Advances in the treatment of congestive heart failure: New approaches for an old disease', Pharmacotherapy, vol. 20, no. 7 I, pp. 787-804.
Skrabal, Maryann Z. ; Stading, Julie A. ; Behmer-Miller, Kathryn A. ; Hilleman, Daniel E. / Advances in the treatment of congestive heart failure : New approaches for an old disease. In: Pharmacotherapy. 2000 ; Vol. 20, No. 7 I. pp. 787-804.
@article{149df9045ff34e7083d4f83ba506041a,
title = "Advances in the treatment of congestive heart failure: New approaches for an old disease",
abstract = "Heart failure is a symptom complex of varied etiology associated with substantial mortality. Approximately 5 million Americans have the disease, with 400,000 new cases diagnosed each year. DeSpite better understanding of its pathophysiology, therapeutic options remain suboptimal and the syndrome remains associated with high rates of hospitalization and loss of economic productivity. Management traditionally included vasodilators, diuretics, and digoxin, with a focus on controlling symptoms and improving ejection fraction and exercise capacity. Drug therapy now is focused on improving survival, with a reduction in health care costs related to hospitalizations. Drugs with a proven benefit in reducing morbidity and mortality are angiotensin- converting enzyme inhibitors, β-blockers, and the combination of hydralazine plus a nitrate. Diuretics, digoxin, dihydropyridine calcium channel blockers, phosphodiesterase inhibitors, catecholamine infusions, amiodarone, left ventricular assist devices, and transplantation are also options.",
author = "Skrabal, {Maryann Z.} and Stading, {Julie A.} and Behmer-Miller, {Kathryn A.} and Hilleman, {Daniel E.}",
year = "2000",
language = "English",
volume = "20",
pages = "787--804",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "7 I",

}

TY - JOUR

T1 - Advances in the treatment of congestive heart failure

T2 - New approaches for an old disease

AU - Skrabal, Maryann Z.

AU - Stading, Julie A.

AU - Behmer-Miller, Kathryn A.

AU - Hilleman, Daniel E.

PY - 2000

Y1 - 2000

N2 - Heart failure is a symptom complex of varied etiology associated with substantial mortality. Approximately 5 million Americans have the disease, with 400,000 new cases diagnosed each year. DeSpite better understanding of its pathophysiology, therapeutic options remain suboptimal and the syndrome remains associated with high rates of hospitalization and loss of economic productivity. Management traditionally included vasodilators, diuretics, and digoxin, with a focus on controlling symptoms and improving ejection fraction and exercise capacity. Drug therapy now is focused on improving survival, with a reduction in health care costs related to hospitalizations. Drugs with a proven benefit in reducing morbidity and mortality are angiotensin- converting enzyme inhibitors, β-blockers, and the combination of hydralazine plus a nitrate. Diuretics, digoxin, dihydropyridine calcium channel blockers, phosphodiesterase inhibitors, catecholamine infusions, amiodarone, left ventricular assist devices, and transplantation are also options.

AB - Heart failure is a symptom complex of varied etiology associated with substantial mortality. Approximately 5 million Americans have the disease, with 400,000 new cases diagnosed each year. DeSpite better understanding of its pathophysiology, therapeutic options remain suboptimal and the syndrome remains associated with high rates of hospitalization and loss of economic productivity. Management traditionally included vasodilators, diuretics, and digoxin, with a focus on controlling symptoms and improving ejection fraction and exercise capacity. Drug therapy now is focused on improving survival, with a reduction in health care costs related to hospitalizations. Drugs with a proven benefit in reducing morbidity and mortality are angiotensin- converting enzyme inhibitors, β-blockers, and the combination of hydralazine plus a nitrate. Diuretics, digoxin, dihydropyridine calcium channel blockers, phosphodiesterase inhibitors, catecholamine infusions, amiodarone, left ventricular assist devices, and transplantation are also options.

UR - http://www.scopus.com/inward/record.url?scp=0033946172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033946172&partnerID=8YFLogxK

M3 - Review article

VL - 20

SP - 787

EP - 804

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 7 I

ER -